Literature DB >> 16235380

Laser photocoagulation for choroidal neovascularisation in pathologic myopia.

G Virgili1, F Menchini.   

Abstract

BACKGROUND: Pathologic myopia is usually defined as the need for a spectacle correction of -6 diopters or higher. Choroidal neovascularisation (CNV) is the most commonly occurring cause of visual loss in people with pathologic myopia. In myopic macular degeneration the occurrence of newly formed vessels in the macula often leads to a fibrotic pigmented scar causing a blind spot in the centre of the visual field.
OBJECTIVES: The primary objective of this review was to examine the effects of laser photocoagulation for CNV associated with pathologic myopia. A secondary objective was to compare the effects of different photocoagulation techniques. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) on The Cochrane Library (Issue 2, 2005), MEDLINE (1966 to July 2005), EMBASE (1980 to July 2005, week 28), LILACS (July 2005) and the reference lists of included studies. SELECTION CRITERIA: We included randomised controlled trials comparing photocoagulation with observation or comparing different photocoagulation techniques in people with CNV associated with myopia of -6 diopters or higher. DATA COLLECTION AND ANALYSIS: Two authors independently assessed the search results for eligibility. MAIN
RESULTS: Two studies were included that enrolled people with CNV located at 100 microns or more from the foveal centre. One study compared photocoagulation with observation. At the final examination, 16/35 participants randomised to photocoagulation versus 31/35 randomised to observation had visual acuity of 20/100 or worse after 6 to 48 months. The second study randomised 27 eyes (26 patients) to photocoagulation with three laser wavelengths (9 eyes per group). The number of eyes losing two or more lines was 2 (577 nm), 3 (590 nm) and 3 (620 nm) after 3 to 17 months. In both studies comparisons were made using outcomes assessed at the final examination. As the final examination took place at different follow-up times it was difficult to interpret the findings and it was impossible to extract data for further analyses. AUTHORS'
CONCLUSIONS: Despite its use over several years the effectiveness of laser photocoagulation for myopic CNV has not been established. Although there was a suggestion of short-term effectiveness in one small study on non-subfoveal CNV the results were potentially biased. Observational studies suggest that the enlargement of the atrophic laser scar after laser treatment of non-subfoveal CNV could be a potentially vision-threatening long-term complication, even in eyes free of CNV recurrence.

Entities:  

Mesh:

Year:  2005        PMID: 16235380     DOI: 10.1002/14651858.CD004765.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  16 in total

1.  How blinding is pathological myopia?

Authors:  S-M Saw
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

2.  Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study.

Authors:  Ming-Chin Yang; Yen-Po Chen; Elise Chia-Hui Tan; Claudia Leteneux; Erin Chang; Carol Hy Chu; Chi-Chun Lai
Journal:  Jpn J Ophthalmol       Date:  2017-01-06       Impact factor: 2.447

3.  [Statement of the Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society), the Retinologische Gesellschaft (German Retina Society) and the Berufsverband der Augenärzte Deutschlands (German Professional Association of Ophthalmologists) on the therapy of choroidal neovascularization in myopia. State: March 2014].

Authors:  D Pauleikhoff; B Bertram; D Claessens
Journal:  Ophthalmologe       Date:  2014-03       Impact factor: 1.059

4.  Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization.

Authors:  H Nakanishi; A Tsujikawa; Y Yodoi; Y Ojima; A Otani; H Tamura; K Yamashiro; S Ooto; N Yoshimura
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

5.  Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes.

Authors:  Valentina Sarao; Daniele Veritti; Sara Macor; Paolo Lanzetta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-18       Impact factor: 3.117

6.  Laser photocoagulation enhances adeno-associated viral vector transduction of mouse retina.

Authors:  Si Hyung Lee; Peter Colosi; Heuiran Lee; Young-Hoon Ohn; Sung-Woon Kim; Hyung Woo Kwak; Tae Kwann Park
Journal:  Hum Gene Ther Methods       Date:  2013-12-28       Impact factor: 2.396

7.  Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.

Authors:  M Rinaldi; F Semeraro; F Chiosi; A Russo; M R Romano; M C Savastano; R dell'Omo; C Costagliola
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-28       Impact factor: 3.117

Review 8.  Laser-assisted subepithelial keratectomy (LASEK) versus photorefractive keratectomy (PRK) for correction of myopia.

Authors:  Shi-Ming Li; Siyan Zhan; Si-Yuan Li; Xiao-Xia Peng; Jing Hu; Hua Andrew Law; Ning-Li Wang
Journal:  Cochrane Database Syst Rev       Date:  2016-02-22

9.  Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization.

Authors:  Paolo Milani; Amedeo Massacesi; Stefano Ciaccia; Marco Setaccioli; Stefania Moschini; Fulvio Bergamini
Journal:  Clin Ophthalmol       Date:  2012-11-19

Review 10.  Myopic choroidal neovascularisation: current concepts and update on clinical management.

Authors:  Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2014-07-01       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.